[1]Tsukamoto T, Matsubara T, Akashi Y, Kondo M, Yanagita M.Annual Iron Loss Associated with Hemodialysis. [J].Am J Nephrol, 2016, 43(1):32-38
[2]Sargent JA, Acchiardo SR.Iron requirements in hemodialysis. Blood Purif. 2004. 22(1): 112-23;
[3]中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2018修订版). 中华肾脏病杂志. 2018. 34(11): 860-866;
[4]Locatelli F, Bárány P, Covic A, et al.Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement[J]. Nephrol Dial Transplant, 2013, 28:1346-59;
[5]Mikhail A, Brown C, Williams JA, et al.Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease[J]. BMC Nephrol, 2017, 18:345;
[6]al MJP.KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease, 2012;
[7]Hasegawa T, Koiwa F, Akizawa T.Anemia in conventional hemodialysis: Finding the optimal treatment balance[J]. Semin Dial, 2018, 31:599-606.
[8]张周沧.维持性血液透析患者静脉铁剂在贫血治疗中的争议[J]. 中国血液净化, 2015, 14:518-520.
[9]Charytan DM, Pai AB, Chan CT, et al.Considerations and challenges in defining optimal iron utilization in hemodialysis[J]. J Am Soc Nephrol, 2015, 26:1238-47.
[10]Zager RA, Johnson AC, Hanson SY.Parenteral iron therapy exacerbates experimental sepsis. Kidney Int. 2004. 65(6): 2108-12.
[11]Lim PS, Wei YH, Yu YL, et al.Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy[J]. Nephrol Dial Transplant, 1999, 14:2680-7.
[12]Bailie GR, Larkina M, Goodkin DA, et al.Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality[J]. Kidney Int, 2015, 87:162-8.
[13]Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al.Time-dependent associations between iron and mortality in hemodialysis patients[J]. J Am Soc Nephrol, 2005, 16:3070-80.
[14]Feldman HI, Santanna J, Guo W, et al.Iron administration and clinical outcomes in hemodialysis patients[J]. J Am Soc Nephrol, 2002, 13:734-44.
[15]Deicher R, Ziai F, Cohen G, et al.High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity[J]. Kidney Int, 2003, 64:728-36.
[16]Mencacci A, Cenci E, Boelaert JR, et al.Iron overload alters innate and T helper cell responses to Candida albicans in mice[J]. J Infect Dis, 1997, 175:1467-76.
[17]Kuo KL, Hung SC, Wei YH, et al.Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients[J]. J Am Soc Nephrol, 2008, 19:1817-26.
[18]Ishida JH, Johansen KL.Iron and infection in hemodialysis patients[J]. Semin Dial, 2014, 27:26-36.
[19]Deicher R, H?rl WH.Intravenous iron: the iatrogenic kick to lose control over oxygen?[J]. Kidney Blood Press Res, 2002, 25:284-8;
[20]Neven E, De Schutter TM, Behets GJ, et al.Iron and vascular calcification. Is there a link?[J]. Nephrol Dial Transplant, 2011, 26:1137-45;
[21]Schiesser D, Binet I, Tsinalis D, et al.Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients[J]. Nephrol Dial Transplant, 2006, 21:2841-5.
[22]Gafter-Gvili A, Schechter A, Rozen-Zvi B.Iron Deficiency Anemia in Chronic Kidney Disease[J]. Acta Haematol, 2019, 142:44-50.
[23]娄奕萌, 王宗谦, 梁焱, 等.静脉铁不同给药方案对维持性血液透析患者贫血及氧化应激反应的影响[J]. 中国血液净化, 2009, 8:608-611.
[24]Herrera J, Nava M, Romero F, et al.Melatonin prevents oxidative stress resulting from iron and erythropoietin administration[J]. Am J Kidney Dis, 2001, 37:750-7.
[25]Macdougall IC, White C, Anker SD, et al.Intravenous Iron in Patients Undergoing Maintenance Hemodialysis[J]. N Engl J Med, 2019, 380:447-458.
[26]Miskulin DC, Tangri N, Bandeen-Roche K, et al.Intravenous iron exposure and mortality in patients on hemodialysis[J]. Clin J Am Soc Nephrol, 2014, 9:1930-9.
[27]Hougen I, Collister D, Bourrier M, et al.Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis[J]. Clin J Am Soc Nephrol, 2018, 13:457-467.
